Tara Baetz

2.6k total citations
71 papers, 1.5k citations indexed

About

Tara Baetz is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Tara Baetz has authored 71 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 25 papers in Pathology and Forensic Medicine and 18 papers in Molecular Biology. Recurrent topics in Tara Baetz's work include Lymphoma Diagnosis and Treatment (25 papers), Cancer Immunotherapy and Biomarkers (23 papers) and CAR-T cell therapy research (19 papers). Tara Baetz is often cited by papers focused on Lymphoma Diagnosis and Treatment (25 papers), Cancer Immunotherapy and Biomarkers (23 papers) and CAR-T cell therapy research (19 papers). Tara Baetz collaborates with scholars based in Canada, United States and Italy. Tara Baetz's co-authors include Adi Kartolo, Wilma M. Hopman, Michael Crump, D. Scott Ernst, Ralph M. Meyer, Stephen Couban, Kevin Imrie, Elizabeth A. Eisenhauer, Robert E. Myers and Keyue Ding and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Tara Baetz

65 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tara Baetz Canada 20 904 514 391 317 261 71 1.5k
B.Y. Yeap United States 20 805 0.9× 595 1.2× 1.0k 2.6× 563 1.8× 295 1.1× 65 2.0k
Kim Linton United Kingdom 24 1.1k 1.2× 1.2k 2.2× 376 1.0× 421 1.3× 542 2.1× 122 2.2k
Lucia Nogová Germany 24 683 0.8× 698 1.4× 642 1.6× 314 1.0× 184 0.7× 86 1.5k
Robert C. Hermann United States 15 1.0k 1.1× 449 0.9× 868 2.2× 397 1.3× 284 1.1× 38 1.8k
Francesco Turturro United States 19 637 0.7× 546 1.1× 159 0.4× 580 1.8× 253 1.0× 64 1.4k
Hyeon‐Seok Eom South Korea 24 864 1.0× 679 1.3× 95 0.2× 412 1.3× 301 1.2× 133 1.7k
Gamal-Andre Banat Germany 10 726 0.8× 890 1.7× 230 0.6× 210 0.7× 534 2.0× 12 1.4k
Hongliang Shi United States 20 904 1.0× 703 1.4× 272 0.7× 941 3.0× 511 2.0× 44 2.0k
Héctor Soto Parrà Italy 24 1.3k 1.5× 257 0.5× 1.6k 4.2× 258 0.8× 168 0.6× 101 2.3k
Mihaela Munteanu United States 14 538 0.6× 548 1.1× 107 0.3× 195 0.6× 339 1.3× 61 1.1k

Countries citing papers authored by Tara Baetz

Since Specialization
Citations

This map shows the geographic impact of Tara Baetz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tara Baetz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tara Baetz more than expected).

Fields of papers citing papers by Tara Baetz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tara Baetz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tara Baetz. The network helps show where Tara Baetz may publish in the future.

Co-authorship network of co-authors of Tara Baetz

This figure shows the co-authorship network connecting the top 25 collaborators of Tara Baetz. A scholar is included among the top collaborators of Tara Baetz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tara Baetz. Tara Baetz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Yao, Xiaomei, Tara Baetz, Alexandra Easson, et al.. (2024). Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review. Surgical Oncology. 54. 102077–102077. 3 indexed citations
4.
Kartolo, Adi, Wilma M. Hopman, Linda Liu, et al.. (2022). Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma. Current Oncology. 29(3). 1501–1513. 1 indexed citations
5.
Nguyen, Paul, et al.. (2022). A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma. BMC Cancer. 22(1). 720–720. 6 indexed citations
6.
Hopman, Wilma M., et al.. (2021). Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors. Melanoma Research. 31(3). 258–263. 11 indexed citations
7.
Yeung, Cynthia, et al.. (2021). Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases. Journal of Immunotherapy. 44(9). 362–370. 19 indexed citations
8.
9.
Kartolo, Adi, et al.. (2018). The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population. Journal of Geriatric Oncology. 10(3). 411–414. 55 indexed citations
10.
Lévesque, Linda E., et al.. (2018). Brief Report: Increase in Melanoma Incidence in Ontario. Journal of Cutaneous Medicine and Surgery. 22(5). 476–478. 12 indexed citations
11.
Hanna, Timothy P., Tara Baetz, Jianfeng Xu, et al.. (2017). Mental Health Services Use by Melanoma Patients Receiving Adjuvant Interferon: Association of Pre-treatment Mental Health Care with Early Discontinuation. Current Oncology. 24(6). 503–512. 2 indexed citations
12.
13.
Kuruvilla, John, David MacDonald, C. Tom Kouroukis, et al.. (2015). Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood. 126(6). 733–738. 28 indexed citations
14.
Cheung, Matthew C., Annette E. Hay, Michael Crump, et al.. (2015). Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12. JNCI Journal of the National Cancer Institute. 107(7). 20 indexed citations
15.
16.
Farmer, Patricia, C. Blake Gilks, Julia Brettschneider, et al.. (2011). Differential expression of cell-cycle regulatory proteins defines distinct classes of follicular lymphoma. Human Pathology. 42(7). 972–982. 7 indexed citations
17.
Johri, Amer M., et al.. (2009). Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome. Canadian Journal of Cardiology. 25(6). e210–e212. 43 indexed citations
18.
LeBrun, David P., Tara Baetz, Patricia Farmer, et al.. (2008). Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs. Clinical Cancer Research. 14(2). 478–487. 6 indexed citations
19.
Baetz, Tara, Elizabeth A. Eisenhauer, Lillian L. Siu, et al.. (2006). A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Investigational New Drugs. 25(3). 217–225. 25 indexed citations
20.
Ernst, D. Scott, Elizabeth A. Eisenhauer, Nancy Wainman, et al.. (2005). Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma. Investigational New Drugs. 23(6). 569–575. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B.Y. Yeap Breakdown of academic impact, for papers by Kim Linton Breakdown of academic impact, for papers by Lucia Nogová Breakdown of academic impact, for papers by Robert C. Hermann Breakdown of academic impact, for papers by Francesco Turturro Breakdown of academic impact, for papers by Hyeon‐Seok Eom Breakdown of academic impact, for papers by Gamal-Andre Banat Breakdown of academic impact, for papers by Hongliang Shi Breakdown of academic impact, for papers by Héctor Soto Parrà Breakdown of academic impact, for papers by Mihaela Munteanu
Rankless by CCL
2026